menu
    • menu

    Company profile for Cadrenal Therapeutics

    NEW Drugs in Dev: 2
    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Virtual Booth

    Contact Supplier

    Sharp is a leader in commercial packaging, clinical services, and sterile manufacturing.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    As a CDMO, Mikart offers integrated CDMO services for Solid Dose & Non-sterile Liquid formulations.

    Virtual Booth

    Contact Supplier

    Trusted Global CDMO Partner Delivering End-to-End Pharma Manufacturing & Development Solutions.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    We are a clinical-stage biopharmaceutical company focused on advancing the development of our lead drug candidate, tecarfarin, a late-stage novel therapy with orphan drug indication for the prevention of systemic thromboembolism in patients with end-stage renal disease and atrial fibrillation. We are committed to bringing this novel therapy to the market to help improve the lives of the thousands of individuals who suffer fr...
    We are a clinical-stage biopharmaceutical company focused on advancing the development of our lead drug candidate, tecarfarin, a late-stage novel therapy with orphan drug indication for the prevention of systemic thromboembolism in patients with end-stage renal disease and atrial fibrillation. We are committed to bringing this novel therapy to the market to help improve the lives of the thousands of individuals who suffer from this very serious condition. Our mission is to build a company with a foundation of product candidates that significantly improve quality of life and patient outcomes for individuals with cardiorenal diseases.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Cadrenal TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    822 North A1A Ponte Vedra, FL 32082
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.cadrenal.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/cadrenal/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    RDD

    RDD

    Not Confirmed

    envelop Contact Supplier

    RDD

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Cadrenal Reports Q1 2026 Results and Phase 3 Update on CAD-1005
    Cadrenal Reports Q1 2026 Results and Phase 3 Update on CAD-1005

    07 May 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/05/07/3290023/0/en/cadrenal-therapeutics-reports-first-quarter-2026-financial-results-and-provides-phase-3-development-update-on-cad-1005-following-end-of-phase-2-meeting-with-fda.html

    GLOBENEWSWIRE
    07 May 2026
    Share Share
    Cadrenal's Ph3 for CAD-1005 in Heparin-Induced Thrombocytopenia
    Cadrenal's Ph3 for CAD-1005 in Heparin-Induced Thrombocytopenia

    30 Apr 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/04/30/3284867/0/en/cadrenal-therapeutics-announces-end-of-phase-2-meeting-with-the-fda-and-pivotal-phase-3-registration-path-for-cad-1005-in-heparin-induced-thrombocytopenia-hit.html

    GLOBENEWSWIRE
    30 Apr 2026
    Share Share
    Cadrenal Therapeutics Reports Q4 2025, CAD-1005 HIT Results
    Cadrenal Therapeutics Reports Q4 2025, CAD-1005 HIT Results

    31 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/31/3265537/0/en/Cadrenal-Therapeutics-Reports-Fourth-Quarter-2025-Financial-Results-Provides-Corporate-Update-on-CAD-1005-Program-for-HIT-Following-End-of-Phase-2-FDA-Meeting.html

    GLOBENEWSWIRE
    31 Mar 2026
    Share Share
    Cadrenal Therapeutics Showcases 12-LOX Inhibition Research
    Cadrenal Therapeutics Showcases 12-LOX Inhibition Research

    12 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/12/3254535/0/en/Cadrenal-Therapeutics-Highlights-Research-Supporting-12-LOX-Inhibition-in-Reducing-Inflammation-in-Obesity-and-Type-2-Diabetes.html

    GLOBENEWSWIRE
    12 Mar 2026
    Share Share
    Cadrenal Therapeutics Expands 12-LOX Inhibitor Platform
    Cadrenal Therapeutics Expands 12-LOX Inhibitor Platform

    02 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/02/3247318/0/en/Cadrenal-Therapeutics-Highlights-Recent-12-LOX-Inhibitor-Platform-Expansion.html

    GLOBENEWSWIRE
    02 Mar 2026
    Share Share
    Cadrenal Therapeutics Reports Positive Ph 2 Results for CAD-1005
    Cadrenal Therapeutics Reports Positive Ph 2 Results for CAD-1005

    24 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/24/3243602/0/en/Cadrenal-Therapeutics-Announces-Phase-2-Results-with-Encouraging-Reductions-in-Thrombotic-Events-for-CAD-1005-in-HIT-Supporting-Clinical-Advancement.html

    GLOBENEWSWIRE
    24 Feb 2026
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search